176 results about "Anticoagulation Agents" patented technology

The invention provides an abnormal blood sampling inspection data evaluation processing method and system of a blood sampling system. Wherein the diffusion track dynamic state of an anticoagulant-blood contact surface in a blood sampling tube is tracked in real time, dielectric response waveform distortion characteristics on the two sides are synchronously collected through a capacitance sensor array, and diffusion form parameters are generated; curvature sudden change is analyzed to trigger an acoustic fluid device to modulate audio frequency and flow velocity, and a composite disturbance field is formed; performing capacitance axial scanning on the disturbed mixed fluid, extracting phase angle offset and gradient abrupt change point coordinates, and constructing a dielectric anomaly three-dimensional map; matching a standard dielectric model, positioning a coordinate set of a concentration gradient imbalance area and a coordinate set of an eddy current attenuation area, and generating an anticoagulant abnormal index and a mixed defect matrix in combination with phase angle offset difference; and establishing a data anomaly degree evaluation function based on the anomaly index and the defect matrix, dynamically associating a clinical error threshold, and outputting a test evaluation result. According to the invention, anticoagulant diffusion can be monitored in real time, and the mixing quality error can be accurately evaluated.

The invention provides a sample pretreatment automation method for flow cytometry, and belongs to the technical field of sample pretreatment for flow cytometry. A biological sample to be detected is collected and placed in a collection tube containing an EDTA-K2 anticoagulant for pretreatment; an automatic pipetting system is used for carrying out incubation reaction on an anticoagulant whole blood sample and an intelligent matching fluorescence labeling antibody mixed solution, and a double-layer game optimization verification system is used for verifying the rationality of an antibody adding proportion and reaction condition parameters; carrying out fluorescence characteristic readability index prediction on the incubated cell suspension by adopting an intelligent dilution parameter regulator model, dynamically adjusting hemolysis parameters and suspension conditions, and adding 1 * hemolysin working solution by using an automatic liquid adding device to carry out hemolysis treatment so as to finish pretreatment; the technical problems that in the pretreatment process of flow cytometry detection samples, parameters are often based on artificial experience, and the reproducibility and standardization degree of detection results are insufficient are solved.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

The invention provides autologous platelet-containing plasma gel and a preparation method and application thereof, and relates to the technical field of biological medicine and tissue engineering.The preparation method comprises the following steps that peripheral venous blood of a patient is extracted and added into a centrifugal tube mixed with a sodium citrate anticoagulant; putting the centrifugal tube into a centrifugal machine for centrifuging, and taking upper-layer plasma; wherein the upper-layer plasma refers to plasma between the upper-layer liquid level and the lower-layer red blood cell layer by 1mm; the centrifugal speed ranges from 1300 r / min to 1700 r / min; the centrifugation time is 3-5 min; under a sterile condition, preparing a calcium gluconate / thrombin mixed solution; and dropping the calcium gluconate / thrombin mixed solution into the upper plasma, mixing, and solidifying to obtain the autologous platelet-containing plasma gel. After one-time centrifugation, upper-layer full-layer plasma is extracted, the volume of the prepared gel is far larger than that of a traditional method, the utilization rate of whole blood platelets and fibrinogen is close to 100%, and regeneration and repair of large-area tissue wounds can be met.

The present invention relates to methods for determining a blood gas parameter and / or a basic metabolic panel parameter in a blood sample comprising combining the blood sample with an anti-coagulant and an anti-platelet agent, and determining said blood gas parameter and / or parameter in the sample. In some aspects, the invention relates to determining said parameters in samples that have been subjected to pre-analytical stress.

The invention discloses a high-precision detection method of abnormal plasma cells, which comprises the following steps: preparing a film, immediately and uniformly mixing the extracted marrow fluid with an anticoagulant, sequentially diluting and centrifuging the marrow, then collecting a leukocyte layer, washing with a fluid medium RPMI 1640 / 5% FBS for at least one time, then counting the cells, adjusting the cell concentration to 1 * 10 < 6 > / ml, adding 100 [mu] l of the cell suspension into a funnel of a cell centrifugal smear device, centrifuging at room temperature for 1000 revolutions, continuing for 5 minutes, and preserving a slide filled with the cell suspension; the preparation of FISH cells comprises the following steps: firstly, preparing and pretreating a 90% formamide / 2 * SSC solution; according to the method, the accuracy and the efficiency of abnormal plasma cell detection are improved by combining an intelligent AI recognition model and a fluorescence in situ hybridization (FISH) technology. The application of the intelligent AI recognition model can reduce personal errors and improve the recognition capability of fluorescence signals, thereby improving the accuracy of detection results.

The invention discloses blood component single sampling equipment capable of monitoring in real time in the field of blood treatment equipment. The equipment comprises a blood sampling module, a centrifugal separation module, a component collection module and an anticoagulant conveying module, and further integrates a multi-dimensional real-time monitoring system and a closed-loop self-adaptive regulation and control module. The multi-dimensional real-time monitoring system comprises an online micro-fluidic component detection unit, a physiological parameter monitoring unit and an equipment operation monitoring unit, can realize real-time online detection of blood component purity, cell activity and pollutant residue in the separation process, and synchronously monitors circulation physiological parameters of a blood donor and an equipment operation state at the same time; the closed-loop self-adaptive regulation and control module can dynamically adjust parameters such as the centrifugal rotating speed, the fluid pump speed and the anticoagulant ratio according to real-time monitoring data, and precise closed-loop control over the separation process is achieved. The quality stability of blood single-sampling components can be remarkably improved, meanwhile, the operation risk is greatly reduced, and the method is suitable for clinical blood component single-sampling and preparation scenes.

The invention discloses a processing method of pigeon blood tofu. The content of protein peptide and the absorbable utilization degree of protein in a pigeon blood tofu finished product are improved. The method comprises the following steps: (1) anticoagulant treatment: adding an anticoagulant into fresh pigeon blood, and uniformly mixing; (2) extracting the pigeon blood protein: adjusting the pH value of the anticoagulant pigeon blood to the isoelectric point of the pigeon blood protein, centrifuging, and collecting the precipitate to obtain the pigeon blood protein; (3) pre-digestion treatment: carrying out enzymolysis pre-digestion treatment on the pigeon blood protein by using pepsin and trypsin in sequence; (4) making pigeon blood bean curds: adding guar gum, carrageenan, calcium chloride and water into the pre-digested pigeon blood protein, performing reflux treatment by using a colloid mill, and then heating gel to obtain the pigeon blood bean curds; (5) inoculating and fermenting: inoculating debaryomyces hansenii suspension into the pigeon blood tofu, and fermenting; and sterilizing the fermented pigeon blood tofu with steam, and cooling to obtain the pigeon blood tofu product.

The invention relates to an enzymolysis technology and a microwave-assisted extraction technology in a bioengineering technology, in particular to a method for extracting sika deer blood polypeptide through a microwave-assisted enzyme method and application of the sika deer blood polypeptide in anti-fatigue food. Treating the deer blood by using a composite anticoagulant containing sodium citrate, centrifuging, and freezing and thawing to obtain a lysate; carrying out microwave-assisted malic acid acidification, carrying out staged enzymolysis by using a compound enzyme composed of bromelain according to a ratio of 4: 3: 2, and introducing carbon dioxide to control the pH value; performing enzyme deactivation and centrifugal ultrafiltration to obtain a crude product, purifying the crude product through an ion exchange column and a gel column, and performing Maillard reaction modification with chitosan oligosaccharide; and finally preparing the anti-fatigue food with maltodextrin as an auxiliary material. According to the method, the yield of the sika deer blood polypeptide is greatly improved, the proportion of high-activity small molecule peptide is extremely high, the stability and bioavailability of the modified polypeptide are remarkably improved, and the bitter taste is reduced; the efficacy of the prepared anti-fatigue food is superior to that of similar products, and high-value utilization of deer blood resources is promoted.

In various embodiments, disclosed herein are methods of assessing therapeutic efficacy of an anticoagulant. Preferably, the method comprising providing a blood sample; perfusing the blood sample over a surface coated with collagen or immobilized rTF; measuring platelet aggregation and fibrin deposition on the surface coated with collagen or immobilized rTF; and assessing therapeutic efficacy of the anticoagulant based on the volume of platelet aggregates and / or deposited fibrin.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The present invention discloses a modified polyimide hollow fiber membrane. The hollow fiber membrane comprises a polysulfone / polyethersulfone matrix component and a modified polyimide hydrophobic polymer containing 30% to 100% of the matrix component by weight. The modified polyimide hydrophobic polymer is prepared by mixing water, a strongly polar solvent, an alkaline catalyst, and a polyimide resin at 80 to 120°C for a partial hydrolysis reaction for 5 to 10 hours. After the solution is cooled, the pH is adjusted to 1 to 3 to remove water. A polyamine is first added and stirred for 2 to 4 hours. A carboxyl-containing anticoagulant is then added and a grafting reaction is carried out for 12 to 48 hours to obtain the modified polyimide hydrophobic polymer. The hollow fiber membrane prepared by the present invention has a good ultrafiltration coefficient, significantly improved hydrophilicity, effectively reduces the deposition of prothrombin and fibrin, and significantly improves the anticoagulant effect, making it suitable for use as a blood purification material.

To provide a factor Xa reagent.SOLUTION: Exemplary compositions include Factor Xa, a substrate, one or more guanidine derivatives, and in some cases heparin. An exemplary method of detecting an anticoagulant in a sample includes combining or contacting a composition with a sample and measuring factor Xa activity based on substrate status. The composition modulates the activity of factor Xa in the sample, and the modulation includes a reduction in the rate of clotting of the sample caused by factor Xa. The presence of an anticoagulant is based on the activity of factor Xa.SELECTED DRAWING: None

Novel methods, compositions and kits for using lymphatic targeting anti-thrombosis (LTAT) molecules are provided herein. The LTAT molecules can be used to treat or prevent lymphatic thrombosis resulting particularly from infection or inflammation in the intestine.

The application discloses a kind of plasma collection systems, belongs to the field of plasma collection.A kind of plasma collection system, including equipment box, still including separation box being fixed in the top of equipment box, separation box is provided with the filter part of separating blood and plasma in, wherein, the top of separation box is provided with liquid storage ring, drop adding part for adding anticoagulant into separation box is set on the liquid storage ring;Refrigerator is fixed on the equipment box, refrigeration bin is opened in the side wall of equipment box, and the output end of refrigerator is communicated with the inner cavity of refrigeration bin;The repulsion of piston plate and magnetic plate makes the air pressure in separation box continuously reduce, so that blood moves more quickly into separation box, effectively improves blood collection efficiency;And cooperate with rotary shaft to drive filter hopper to rotate, so that filter hopper generates centrifugal force effect, so that plasma component in blood more quickly and effectively passes through filter membrane, effectively improves separation effect.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

To provide a blood collection container capable of reducing the amount of leukocytes mixed into plasma even when blood is centrifuged several days after collection. The blood collection container according to the present invention comprises a blood collection container body, a plasma separation material contained in the blood collection container body, and an aqueous solution contained in the blood collection container body, wherein the aqueous solution contains an anticoagulant and a lithium salt different from the anticoagulant.

Disposable cartridges and methods for detecting and classifying an anticoagulant at a therapeutically relevant amount or higher in a patient. The cartridges include a plurality of chambers, as well as fluidic couplings between chambers. Calcium chloride, Russel Viper Venom (RVV), an ecarin reagent, a Factor Xa reagent, protamine, kaolin, tissue factor, and combinations thereof may be included in a given chamber.

The application relates to the technical field of blood cell separation machines, in particular to a blood cell separation machine device for hematology nursing, which comprises a stirring mechanism, a feeding mechanism, a drawing mechanism, a centrifugal mechanism and a separation mechanism. The upper end of the stirring mechanism is provided with the feeding mechanism, the lower end of the feeding mechanism is provided with the drawing mechanism, the lower end of the drawing mechanism is provided with the centrifugal mechanism, and the centrifugal mechanism is provided with the separation mechanism at one end. The rotating stirring blade can uniformly mix blood and anticoagulant, preventing the blood from coagulating before centrifugation. The second sliding block and the first connecting pipe are in sliding cooperation, so that the anticoagulant can be automatically and quantitatively added into the cylinder. The second sleeve can draw the blood in the cylinder to the test tube when the first motor stops rotating. The sliding pipe and the second fixed block can quickly take out the separated blood plasma. The third sliding block can be pulled outward to take out the remaining blood cells conveniently and quickly.

Provided herein are devices, systems, methods, and compositions, including compositions for coupling to a surface of an implantable article, the compositions comprising an anticoagulant comprising a direct factor Xa inhibitor and at least one of (a) an antiplatelet drug, (b) an anticoagulant comprising a direct factor IIa inhibitor, and (c) an anti-inflammatory drug comprising colchicine.

The present invention relates to the field of biomedical technologies and provides a method for efficiently capturing neutrophils from peripheral blood for single-cell sequencing by lysing red blood cells. The method includes the following steps: collecting human peripheral blood into an anticoagulant tube containing ethylenediaminetetraacetic acid; taking the ethylenediaminetetraacetic acid anticoagulated whole blood, adding a red blood cell lysate, lysing at room temperature, waiting until the turbid mixed blood solution becomes clear and transparent, waiting for 1 minute, then adding a FACS cell resuspension solution to terminate red blood cell lysis, and centrifuging; adding the FACS cell resuspension solution to slowly resuspend the cells, and centrifuging; adding the FACS cell resuspension solution to slowly resuspend the cells, and centrifuging; adding a phosphate buffer solution to slowly resuspend the cells, and centrifuging. By selecting a suitable anticoagulant, precisely controlling the red blood cell lysis conditions, and performing meticulous cell resuspension and centrifugation operations, the present invention can ensure high neutrophil activity and a low cell debris rate, provide a suitable single-cell suspension for single-cell RNA sequencing, and help analyze the characteristics and functions of various neutrophil subsets.

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

The invention belongs to the technical field of clinical medicine, and relates to a method for extracting autologous platelet-rich plasma, which comprises the following steps of: adding an anticoagulant into an injector I in advance, then extracting autoblood, uniformly mixing for 3-4 times back and forth by virtue of an injector II, then centrifuging for 10 minutes at the speed of 1,500 revolutions per minute, sucking the platelet-rich plasma in the injector I by virtue of an injector III, and extracting the platelet-rich plasma in the injector II by virtue of an injector III. And centrifuging again, and discarding the supernatant by using an injector IV to obtain a high-concentration PRP finished product. According to the extraction method, in the extraction process, blood is uniformly mixed for 3-4 times back and forth between an injector I and an injector II, and the blood is centrifuged for 10 minutes at the speed of 1500 r / min in the first centrifugation process, so that the platelet concentration in the finally extracted PRP is remarkably improved compared with the platelet concentration in peripheral blood; the red blood cells reach the quality control target, the white blood cells are obviously reduced, and a set of standardized autologous platelet-rich plasma clinical extraction method which is simple in extraction device, low in consumable cost, simple to operate and high in extraction concentration is formed.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

Methods and systems for the automated collection of plasma from a donor are disclosed. The methods and systems deliver anticoagulant to whole blood and / or to selected and separated components at selected times to provide a sufficient amount of anticoagulant to the selected components to prevent coagulation and / or flocculation. The methods and systems limit the amount of anticoagulant returned to the donor and maximize the amount of collected plasma. Methods and systems for maximize the collection of IgG based on a measured level of total plasma protein are also disclosed.

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

The invention discloses a method for extracting immune globulin in pig blood and application of the method, and relates to the technical field of fresh pig blood extraction.The method comprises the following steps that S1, after fresh pig blood and an anticoagulant are evenly mixed, low-temperature standing and centrifugation are conducted, plasma liquid is separated out and stored, and the plasma liquid is obtained; s2, extracting the plasma liquid through three times of ethanol reaction to obtain an immune globulin crude product; s3, carrying out three-stage purification on the immune globulin crude product, namely precipitation treatment, hollow fiber ultrafiltration column dealcoholization treatment and affinity chromatography treatment, and finally, dialyzing and freeze-drying to obtain an immune globulin IgG finished product. According to the method for extracting the immune globulin in the pig blood, the extraction rate and the purity of the immune globulin IgG can be effectively improved.

The invention relates to the field of blood detection reagents, in particular to a blood free DNA stabilizer and application thereof. Every 100 ml of the blood free DNA stabilizer comprises 0.5-5 g of a buffer agent, 2-20 g of an aldehyde fixing agent, 15-20 g of an anticoagulant, 10-50 g of a cell stabilizer, 2.5-12.5 g of a nuclease inhibitor, and the balance of ultrapure water. The pH value of the blood free DNA stabilizer is 6.8 to 7.8; the cell stabilizer is selected from one or two or more than two of polysucrose-50, polysucrose-70, polysucrose-400, polyethylene glycol-4000, polyethylene glycol-6000, polyethylene glycol-8000 and glycine betaine. Preferably, the cell stabilizer is selected from polysucrose-70, and every 100 ml of the blood free DNA stabilizer contains 10 g of polysucrose-70. The stabilizer provided by the invention is low in toxicity and low in cost, and can maintain free DNA stability and inhibit blood cell genome release at normal temperature for 10 days, so that the storage cost and the transportation cost of a blood sample are effectively reduced, and the detection accuracy of the blood free DNA is improved.

The embodiments herein provide hemostatic compositions, methods, and kits comprising composite polymer particles. Upon contact with blood or other physiological fluids, the composite particles adsorb fluid and aggregate into a shape-retentive mass that halts bleeding. In certain embodiments, the particles comprise polymers of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, or combinations thereof. The particles may be used alone or blended with additional hemostatic agents. Methods of inducing hemostasis are provided for diffuse oozing, or surgical, mucosal, organ surface, fragile tissue or traumatic bleeding, including in patients receiving anticoagulant or antiplatelet therapy. Kits comprising sterile packages of composite particles, optionally with applicators, substrates, or sprays, are disclosed. The compositions exhibit intrinsic hemostatic activity and synergistically enhance the performance of conventional hemostats, achieving rapid clotting. After hemostasis is achieved, the compositions remain in situ as a conforming protective layer, reducing the need for additional covering materials and decreasing risk of re-bleeding.